HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA denies sunscreen petition

This article was originally published in The Rose Sheet

Executive Summary

FDA can not stay effective date of any pending decision to exempt "sunscreen face products" from OTC sunscreen monograph or effective date of any labeling requirement, agency informs Playtex Jan. 31. Citizen petition requesting stays of action is denied because "there is no 'decision' or 'effective date'...which can be stayed," FDA says. Banana Boat manufacturer/marketer submitted petition urging uniform labeling for sunscreen products in late 2000 in opposition to cosmetics industry requests that products for face, hands and neck be granted labeling exemptions (1"The Rose Sheet" Jan. 22, 2001, p. 9)...

You may also be interested in...



Sunscreen Uniform Labeling Endorsed By Playtex, Contested By CTFA

Uniform labeling on all sunscreen products is necessary to eliminate consumer confusion, subsequent misuse and perceived failure of such items, Playtex maintains in comments to FDA Jan. 5.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel